Samsrita Labs

  • Market Cap: Micro Cap
  • Industry: Healthcare Services
  • ISIN: INE579N01018
  • NSEID:
  • BSEID: 539267
INR
20.94
-2.32 (-9.97%)
BSENSE

Dec 26

BSE+NSE Vol: 1.61 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

1.61 k (157.91%) Volume

Shareholding (Sep 2025)

FII

0.00%

Held by 0 FIIs

DII

0.00%

Held by 0 DIIs

Promoter

31.41%

Who are the top shareholders of the Samsrita Labs?

06-Jun-2025

The top shareholders of Samsrita Labs are K Krishnam Raju with 19.58%, followed by M Neela Reddy at 4.67%, and individual investors collectively holding 44.75%. There are no mutual funds or foreign institutional investors involved.

The top shareholders of Samsrita Labs include K Krishnam Raju, who holds the highest promoter share at 19.58%. Following him, the highest public shareholder is M Neela Reddy, with a holding of 4.67%. Additionally, individual investors collectively hold 44.75% of the company's shares. There are no mutual funds or foreign institutional investors currently holding shares in the company.

Read More

Has Samsrita Labs declared dividend?

06-Jun-2025

No Dividend History Available

Who are the peers of the Samsrita Labs?

03-Jun-2025

Samsrita Labs' peers include Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Shree Pacetronix, Adeshwar Meditex, Family Care, and Chennai Meena. Poly Medicure has the highest 1-year return at 24.45%, while Samsrita Labs has a return of 20.20%.

Peers: The peers of Samsrita Labs are Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Shree Pacetronix, Adeshwar Meditex, Family Care, and Chennai Meena.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs, while Good management risk is found at Syngene Intl., Poly Medicure, Indegene, Vijaya Diagnost., and Shree Pacetronix, and the rest. Average management risk is noted at Family Care, while Below Average management risk is seen at Adeshwar Meditex. Growth is Excellent at Family Care, Below Average at Syngene Intl., Dr Lal Pathlabs, Vijaya Diagnost., Shree Pacetronix, and the rest, and Average at Poly Medicure and Indegene. Capital Structure is Excellent at Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., and the rest, Good at Shree Pacetronix, and Below Average at Adeshwar Meditex.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Poly Medicure at 24.45%, while the peer with the lowest is Shree Pacetronix at -60.83%. Samsrita Labs has a 1-year return of 20.20%, which is lower than Poly Medicure's but higher than Shree Pacetronix's. Additionally, the six-month return is negative for Syngene Intl., Poly Medicure, Vijaya Diagnost., Shree Pacetronix, Adeshwar Meditex, Family Care, Chennai Meena, and Samsrita Labs.

Read More

Is Samsrita Labs overvalued or undervalued?

09-Jun-2025

As of April 25, 2023, Samsrita Labs is rated as "risky" and overvalued with a negative PE ratio of -31.10 and an EV to EBIT ratio of -33.30, indicating significant financial struggles compared to peers like MMTC and Optiemus Infra, despite a recent 34.45% return.

As of 25 April 2023, Samsrita Labs has moved from a grade of "does not qualify" to "risky." The company is currently overvalued, as indicated by its negative PE ratio of -31.10 and an EV to EBIT ratio of -33.30. Additionally, the ROCE stands at -3.04%, which further highlights the company's financial struggles.<BR><BR>In comparison to peers, MMTC has a PE ratio of 119.39 and an EV to EBITDA of -70.04, while Optiemus Infra is considered fair with a PE ratio of 82.35 and an EV to EBITDA of 48.56. The stark contrast in these ratios suggests that Samsrita Labs is not only underperforming relative to its peers but also carries significant risk. Despite a recent 34.45% return over the past year, the overall valuation metrics indicate that the stock remains overvalued in the current market context.

Read More

What is the technical trend for Samsrita Labs?

09-Jun-2025

As of May 12, 2025, Samsrita Labs shows a mildly bullish trend supported by positive MACD and KST indicators, despite some short-term weakness indicated by the RSI and daily moving averages.

As of 12 May 2025, the technical trend for Samsrita Labs has changed from sideways to mildly bullish. The weekly MACD is bullish, supporting the positive trend, while the monthly MACD is mildly bullish, indicating a gradual strengthening. The weekly KST is mildly bullish and the monthly KST is bullish, further reinforcing the upward momentum. However, the weekly RSI is bearish, suggesting some short-term weakness. The daily moving averages are mildly bearish, which contrasts with the overall bullish sentiment. Bollinger Bands are mildly bullish on both weekly and monthly time frames, indicating potential for price expansion. Overall, the current stance is mildly bullish, driven primarily by the MACD and KST indicators, despite some mixed signals from the RSI and moving averages.

Read More

When is the next results date for Samsrita Labs?

11-Jul-2025

The next results date for Samsrita Labs is July 18, 2025.

The next results date for Samsrita Labs is scheduled for July 18, 2025.

Read More

Who are in the management team of Samsrita Labs?

16-Jul-2025

As of March 2022, the management team of Samsrita Labs includes K Krishnam Raju (Chairman & Wholetime Director), K.N.V Narendra Kumar (Whole Time Director & CFO), and several independent directors: B Suryaprakash Rao, Aakanksha, Ramamohan Reddy Yarragudi, and A.S.S.V.Srinivas, along with Deepa Dudani as Company Secretary & Compliance Officer.

As of March 2022, the management team of Samsrita Labs includes the following individuals:<BR><BR>1. K Krishnam Raju - Chairman & Wholetime Director<BR>2. B Suryaprakash Rao - Independent Director<BR>3. K.N.V Narendra Kumar - Whole Time Director & CFO<BR>4. Aakanksha - Independent Director<BR>5. Ramamohan Reddy Yarragudi - Independent Director<BR>6. A.S.S.V.Srinivas - Independent Director<BR>7. Deepa Dudani - Company Secretary & Compliance Officer<BR><BR>Each member plays a distinct role in the governance and management of the company.

Read More

What does Samsrita Labs do?

17-Jul-2025

Samsrita Labs Ltd is a micro-cap healthcare services company, formerly known as Dr Habeebullah Life Sciences Limited, with a market cap of INR 27 Cr and reported a net profit of -1 Cr for March 2025. The company has a debt-equity ratio of 0.18 and a return on equity of -2.12%.

Overview: <BR>Samsrita Labs Ltd operates in the healthcare services industry and is categorized as a micro-cap company.<BR><BR>History: <BR>Samsrita Labs Limited was incorporated on January 25, 1996, and was formerly known as Dr Habeebullah Life Sciences Limited until the name change on October 13, 2022. The latest quarterly results reported are for March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: -1 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 27 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.18 <BR>Return on Equity: -2.12% <BR>Price to Book: 2.17<BR><BR>Contact Details: <BR>Address: Sy No 36 Chintalmet X Roads, Upperpally Attapur Rajendra Ng Hyderabad Telangana : 500048 <BR>Phone: 91-90300 57370 <BR>Email: pcproductsindia@gmail.com <BR>Website: https://drhlsl.com

Read More

How big is Samsrita Labs?

24-Jul-2025

As of 24th July, Samsrita Labs Ltd has a market capitalization of 31.00 Cr, categorizing it as a Micro Cap company, with reported Net Sales of 0.00 Cr and a Net Profit loss of 0.26 Cr over the latest four quarters. Shareholder's Funds are valued at 12.26 Cr, and Total Assets amount to 15.55 Cr as of March 2024.

As of 24th July, Samsrita Labs Ltd has a market capitalization of 31.00 Cr, which categorizes it as a Micro Cap company.<BR><BR>In the latest four quarters, Samsrita Labs reported Net Sales of 0.00 Cr. The Net Profit for the same period showed a loss of 0.26 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024. Shareholder's Funds are valued at 12.26 Cr, while Total Assets amount to 15.55 Cr.

Read More

How has been the historical performance of Samsrita Labs?

25-Oct-2025

Samsrita Labs has experienced a declining trend in net sales, dropping from 2.01 Cr in March 2019 to 0.01 Cr in March 2021, alongside increasing losses, with an operating profit of -0.79 Cr in March 2021. The company's total liabilities and assets also decreased significantly during this period, indicating ongoing financial challenges.

Answer:<BR>The historical performance of Samsrita Labs shows a declining trend in net sales and increasing losses over the years.<BR><BR>Breakdown:<BR>Samsrita Labs reported net sales of 0.01 Cr in March 2021, a significant drop from 1.43 Cr in March 2020 and 2.01 Cr in March 2019. The total operating income followed a similar trend, decreasing from 1.43 Cr in March 2020 to 0.01 Cr in March 2021. The company faced substantial losses, with an operating profit (PBDIT) of -0.79 Cr in March 2021, improving slightly from -2.03 Cr in March 2020 but still reflecting ongoing operational challenges. Profit before tax was recorded at -0.80 Cr in March 2021, compared to -2.05 Cr in the previous year, while profit after tax also showed a loss of -0.78 Cr, down from -1.98 Cr in March 2020. The company's total liabilities decreased from 27.75 Cr in March 2020 to 16.58 Cr in March 2021, with total assets also declining from 27.75 Cr to 16.58 Cr in the same period. Cash flow from operating activities remained stagnant, with no inflow or outflow reported in the last two years. Overall, the financial data indicates a challenging period for Samsrita Labs, characterized by declining revenues and persistent losses.

Read More

Why is Samsrita Labs falling/rising?

21-Dec-2025

As of 21-Dec, Samsrita Labs Ltd's stock price is rising to Rs 23.99, up 7.15%, supported by strong relative performance and trading above key moving averages. Increased investor participation and a positive overall trend indicate heightened interest, despite high intraday volatility.

As of 21-Dec, Samsrita Labs Ltd's stock price is rising, currently at Rs 23.99, reflecting an increase of Rs 1.6 or 7.15%. This upward movement is supported by several factors. The stock has outperformed its sector by 5.82% today, indicating strong relative performance. Additionally, the stock has been trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which is a positive sign for investors.<BR><BR>Today, the stock reached an intraday high of Rs 23.99, showcasing its ability to attract buyers despite experiencing a wide trading range of Rs 3.72. Furthermore, there has been a significant increase in investor participation, with delivery volume rising by 449.74% compared to the 5-day average, suggesting heightened interest in the stock.<BR><BR>However, it is important to note that the stock has shown high volatility today, with an intraday volatility of 8.4%. Despite this volatility, the overall trend appears to be positive, contributing to the stock's rise.

Read More

Why is Samsrita Labs falling/rising?

23-Dec-2025

As of 22-Dec, Samsrita Labs Ltd's stock price is at 23.20, down 3.29% today due to decreased investor participation and a longer-term trend of underperformance compared to the benchmark Sensex. Despite recent gains, the stock has shown minimal year-to-date growth and significant declines over the past three and five years.

As of 22-Dec, Samsrita Labs Ltd's stock price is currently at 23.20, reflecting a decrease of 0.79, or 3.29%. This decline can be attributed to several factors. Despite a positive performance over the past week and month, where the stock increased by 3.11% and 6.08% respectively, it has underperformed today, lagging behind the sector by 5.88%. <BR><BR>Additionally, there has been a notable drop in investor participation, with the delivery volume on December 19 falling by 39.54% compared to the 5-day average. This decline in trading activity suggests a lack of interest among investors, which can contribute to downward pressure on the stock price. <BR><BR>While the stock is trading above its moving averages for various periods, the overall year-to-date performance shows a minimal increase of only 0.04%, and a significant decline of 3.89% over the past year. Furthermore, the stock has experienced a substantial drop of 23.81% over the last three years and 43.69% over the last five years, indicating a longer-term trend of underperformance compared to the benchmark Sensex, which has gained 9.51% year-to-date and 40.68% over three years.<BR><BR>In summary, the combination of today's underperformance, declining investor participation, and a longer-term trend of negative returns compared to the benchmark are key factors contributing to the current fall in Samsrita Labs' stock price.

Read More

Why is Samsrita Labs Ltd falling/rising?

24-Dec-2025

As of 23-Dec, Samsrita Labs Ltd's stock price is at 23.15, reflecting a slight decline of -0.22%. The stock has lost value recently, with a total decline of -3.5% over the last two days, and shows concerning long-term performance trends despite some short-term gains.

As of 23-Dec, Samsrita Labs Ltd is experiencing a slight decline in its stock price, currently at 23.15, which reflects a change of -0.05 or -0.22%. This decrease is part of a broader trend, as the stock has been losing value for the last two days, resulting in a total decline of -3.5% during this period. <BR><BR>Despite some positive performance over the past week and month, where the stock has risen by 2.89% and 5.85% respectively, its year-to-date performance shows a slight decline of -0.17%, and it has fallen by -2.20% over the past year. The longer-term outlook is even more concerning, with a significant drop of -20.58% over three years and -40.87% over five years, compared to the Sensex, which has shown positive returns in those periods.<BR><BR>Additionally, there are signs of falling investor participation, as indicated by a drastic reduction in delivery volume, which has decreased by -98.83% against the five-day average. This lack of trading activity may contribute to the stock's downward pressure. However, it is noteworthy that Samsrita Labs is currently trading above its moving averages across various time frames, suggesting some underlying strength despite the recent price drop. Overall, the combination of recent losses, declining investor interest, and the stock's historical performance contributes to the current downward trend in Samsrita Labs Ltd's stock price.

Read More

Why is Samsrita Labs Ltd falling/rising?

25-Dec-2025

As of 24-Dec, Samsrita Labs Ltd's stock price is rising to 23.26, indicating a potential recovery after two days of decline and outperforming the Sensex over the past week. However, a significant drop in delivery volume suggests decreased investor confidence.

As of 24-Dec, Samsrita Labs Ltd's stock price is rising, currently at 23.26, with a change of 0.11 (0.48%) upward. This increase follows a trend reversal after two consecutive days of decline, indicating a potential recovery in the stock's performance. Over the past week, the stock has outperformed the benchmark Sensex, gaining 3.38% compared to the Sensex's 1.00% increase. Additionally, the stock is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which is typically a positive sign for investors.<BR><BR>However, it is important to note that the stock has underperformed its sector by 0.83% today and has experienced a significant drop in delivery volume, which fell by 97.67% against the 5-day average. This decline in investor participation could indicate a lack of confidence or interest among traders. Despite these mixed signals, the recent upward movement in price suggests that there may be a short-term recovery or buying interest in the stock.

Read More

Why is Samsrita Labs Ltd falling/rising?

25-Dec-2025

As of 25-Dec, Samsrita Labs Ltd's stock price is rising to 23.26, indicating a potential recovery after two days of decline. Despite underperforming its sector today and a significant drop in investor participation, the stock has outperformed the Sensex over the past week and is trading above its moving averages, suggesting positive momentum.

As of 25-Dec, Samsrita Labs Ltd's stock price is rising, currently at 23.26, with a change of 0.11 (0.48%) upward. This increase follows a trend reversal after two consecutive days of decline, indicating a potential recovery in the stock's performance. Over the past week, the stock has outperformed the benchmark Sensex, gaining 3.38% compared to the Sensex's 1.00% increase. Additionally, the stock is trading above its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically suggests a positive momentum.<BR><BR>However, it is important to note that the stock has underperformed its sector today by 0.83%. Furthermore, there has been a significant drop in investor participation, with delivery volume on December 23 falling by 97.67% compared to the 5-day average. Despite this decline in participation, the recent upward movement in price indicates a short-term recovery phase for Samsrita Labs Ltd.

Read More

Which are the latest news on Samsrita Labs?

25-Dec-2025

Which are the latest news on Samsrita Labs?

26-Dec-2025

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Loading Valuation Snapshot...
Stock DNA
stock-summary
Industry

Healthcare Services

stock-summary
Market cap

INR 53 Cr (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

30

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.02

stock-summary
Return on Equity

-1.69%

stock-summary
Price to Book

3.43

Revenue and Profits:
Net Sales:
(Quarterly Results - Sep 2025)
Net Profit:
-5 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
9.98%
0%
9.98%
6 Months
-0.9%
0%
-0.9%
1 Year
-11.5%
0%
-11.5%
2 Years
23.18%
0%
23.18%
3 Years
-28.9%
0%
-28.9%
4 Years
-16.57%
0%
-16.57%
5 Years
-46.51%
0%
-46.51%

Samsrita Labs for the last several years.

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions
News

Why is Samsrita Labs falling/rising?

Robust Short-Term Performance Drives Price Rise

The stock’s recent performance has been impressive, with a one-week return of 8.07%, markedly outperforming the Sensex, which declined by 0.52% over the same period. This divergence highlights Samsrita Labs’ resilience amid a broader market pullback. Over the past month, the stock also posted a positive return of 2.73%, exceeding the Sensex’s 0.95% gain. However, it is important to note that the stock’s year-to-date (YTD) return remains modest at 0.47%, lagging behind the Sensex’s 9.12% rise. Longer-term returns reveal challenges, with the stock down 1.60% over one year and significantly underperforming over three and five years, with losses of 19.24% and 51.61% respectively, compared to the Sensex’s robust gains of 37.24% and 8...

Read More
Announcements stock-summary

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011

24-Nov-2025 | Source : BSE

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Krishnam Raju Kalidindi & PACs

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011

17-Nov-2025 | Source : BSE

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Dr Mohammed Aejaz Habeeb & PACs

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011

13-Nov-2025 | Source : BSE

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Syed Ameer Basha Paspala & PACs

Corporate Actions stock-summary
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

No Dividend history available

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-19.89%
EBIT Growth (5y)
-208.40%
EBIT to Interest (avg)
0
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.02
Sales to Capital Employed (avg)
0
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
-7.02%
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
30
Price to Book Value
3.09
EV to EBIT
-9.20
EV to EBITDA
-9.20
EV to Capital Employed
3.13
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-33.99%
ROE (Latest)
-1.69%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Non Institution

Pledged Promoter Holdings

None

Mutual Funds

Held by 0 Schemes

FIIs

Held by 0 FIIs

Promoter with highest holding

Krishnam Raju Kalidindi (12.09%)

Highest Public shareholder

Vase K B Christ (7.73%)

Individual Investors Holdings

64.54%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Sep'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Jun 2025",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is -1,664.29% vs -211.11% in Jun 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.94",
          "val2": "-0.28",
          "chgp": "-1,664.29%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "-4.94",
          "val2": "-0.28",
          "chgp": "-1,664.29%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Consolidated) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-5.21",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.60",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "NA%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Consolidated) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Sep 2025 is -100.00% vs -99.16% in Dec 2020",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in nine months ended Sep 2025 is -507.89% vs 53.94% in Dec 2020",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Dec'20",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.01",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-5.09",
          "val2": "-0.88",
          "chgp": "-478.41%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.62",
          "val2": "-0.76",
          "chgp": "-507.89%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-8,800.00%",
          "chgp": "8,800.00%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 0.00% vs -100.00% in Mar 2024",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is -4.00% vs 64.79% in Mar 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.26",
          "val2": "-0.25",
          "chgp": "-4.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "-0.26",
          "val2": "-0.25",
          "chgp": "-4.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Standalone) - Sep'25 - QoQstock-summary
Sep'25
Jun'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-4.94
-0.28
-1,664.29%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Standalone Net Profit
-4.94
-0.28
-1,664.29%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
Values in Rs Cr.
Net Sales

QoQ Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Jun 2025

Direction Arrows
Standalone Net Profit

QoQ Growth in quarter ended Sep 2025 is -1,664.29% vs -211.11% in Jun 2025

Half Yearly Results Snapshot (Consolidated) - Sep'25stock-summary
Sep'25
Change(%)
Net Sales
0.00
NA
NA
Operating Profit (PBDIT) excl Other Income
-5.21
NA
NA
Interest
0.00
NA
NA
Exceptional Items
0.00
NA
NA
Consolidate Net Profit
-4.60
NA
NA
Operating Profit Margin (Excl OI)
0.00%
NA%
NA
Values in Rs Cr.
Net Sales

Not Applicable: The company has declared_date for only one period

Consolidated Net Profit

Not Applicable: The company has declared_date for only one period

Nine Monthly Results Snapshot (Consolidated) - Sep'25stock-summary
Sep'25
Dec'20
Change(%)
Net Sales
0.00
0.01
-100.00%
Operating Profit (PBDIT) excl Other Income
-5.09
-0.88
-478.41%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-4.62
-0.76
-507.89%
Operating Profit Margin (Excl OI)
0.00%
-8,800.00%
8,800.00%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in nine months ended Sep 2025 is -100.00% vs -99.16% in Dec 2020

Direction Arrows
Consolidated Net Profit

YoY Growth in nine months ended Sep 2025 is -507.89% vs 53.94% in Dec 2020

Annual Results Snapshot (Standalone) - Mar'25stock-summary
Mar'25
Mar'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-0.26
-0.25
-4.00%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Standalone Net Profit
-0.26
-0.25
-4.00%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2025 is 0.00% vs -100.00% in Mar 2024

Direction Arrows
Standalone Net Profit

YoY Growth in year ended Mar 2025 is -4.00% vs 64.79% in Mar 2024

stock-summaryCompany CV
About Samsrita Labs Ltd stock-summary
stock-summary
Samsrita Labs Ltd
Micro Cap
Healthcare Services
Samsrita Labs Limited (Formerly known Dr Habeebullah Life Sciences Limited) was incorporated on January 25, 1996. The Company name was changed from Dr Habeebullah Life Sciences Limited to Samsrita Labs Limited on October 13, 2022.
Company Coordinates stock-summary
Company Details
Sy No 36 Chintalmet X Roads, Upperpally Attapur Rajendra Ng Hyderabad Telangana : 500048
stock-summary
Tel: 91-90300 57370
stock-summary
pcproductsindia@gmail.com
Registrar Details
Venture Capital & Corporate Investments Ltd , 12-10-167,, MIG- 167,, Bharat Nagar Colony, Hyderabad